IV GLP-1 does not reduce death, stroke, organ damage after heart surgery
CHICAGO — Exenatide, an IV GLP-1 receptor agonist, did not improve clinical outcomes compared with placebo in patients undergoing heart surgery, according to the results of the GLORIOUS trial. The researchers also found no differences between a restrictive and a liberal oxygenation strategy in this population.